Concepts (77)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Breast Neoplasms | 3 | 2023 | 509 | 0.430 |
Why?
|
| Ice | 1 | 2007 | 4 | 0.300 |
Why?
|
| Hemoglobin SC Disease | 1 | 2007 | 13 | 0.300 |
Why?
|
| Arm | 1 | 2007 | 147 | 0.270 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2007 | 160 | 0.270 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2023 | 1215 | 0.210 |
Why?
|
| Maytansine | 1 | 2020 | 38 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 3 | 2021 | 2330 | 0.190 |
Why?
|
| Neutropenia | 1 | 2023 | 968 | 0.160 |
Why?
|
| Immunoconjugates | 1 | 2020 | 279 | 0.150 |
Why?
|
| Hyponatremia | 1 | 2018 | 82 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 4975 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 882 | 0.140 |
Why?
|
| Adiponectin | 1 | 2015 | 163 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 588 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2016 | 2326 | 0.110 |
Why?
|
| Sarcoma | 1 | 2023 | 1725 | 0.110 |
Why?
|
| Kidney Neoplasms | 2 | 2016 | 3022 | 0.100 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 3001 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3251 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 1248 | 0.090 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 15694 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 2518 | 0.080 |
Why?
|
| Gangrene | 1 | 2007 | 28 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2023 | 3890 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 15862 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 5159 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 4757 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2023 | 12873 | 0.050 |
Why?
|
| Folate Receptor 1 | 1 | 2020 | 62 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 8873 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2020 | 696 | 0.040 |
Why?
|
| Humans | 10 | 2023 | 261506 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 249 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2021 | 10001 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2016 | 87 | 0.040 |
Why?
|
| Female | 7 | 2023 | 141928 | 0.040 |
Why?
|
| Mutation | 1 | 2014 | 15179 | 0.030 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2014 | 82 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 355 | 0.030 |
Why?
|
| Adult | 4 | 2020 | 77950 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2021 | 32848 | 0.030 |
Why?
|
| Middle Aged | 4 | 2023 | 86204 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2014 | 519 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2014 | 829 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2014 | 1258 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 419 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2016 | 2316 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 1533 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3719 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 1546 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 2218 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 755 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3441 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 1245 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 4298 | 0.020 |
Why?
|
| Neoplasms | 1 | 2015 | 15193 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2014 | 1910 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 4233 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 13658 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 4917 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 4988 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 6089 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12221 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6207 | 0.020 |
Why?
|
| Male | 3 | 2016 | 123000 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 6682 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 5673 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 3230 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 4549 | 0.010 |
Why?
|
| Time Factors | 1 | 2016 | 12926 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 11965 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 17523 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 14289 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 10331 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 37905 | 0.010 |
Why?
|